Androgen receptor and p63 Expression in prostatic Adenocarcinoma – a hospital-based Cross-sectional study

Abstract

Prostate cancer (PCa) ranks among the most prevalent malignancies affecting men around the world. In 2020, prostate cancer was the second most commonly diagnosed cancer in men worldwide, with approximately 1.4 million new cases and 375,000 deaths recorded globally. Androgens are primary sex steroids present in men and have a crucial part in the evolution of the prostate. They are also essential for sexual maturity during puberty. The tumor suppressor gene p63 is a homolog of p53 and serves as a basal cell marker. The study assesses the correlation between tumor cell and stromal androgen receptor (AR) expression with clinicopathological factors and Gleason grade groups. The expression of p63 in PCa, the absence of which is used as an indicator of malignancy, is also evaluated. The AR's quantitative immunohistochemistry (IHC) expression in combination with p63 has not been studied as a predictive indicator for PCa. Hence, we have undertaken the present study. OBJECTIVES • Primary  To evaluate the expression of P63 in prostatic adenocarcinoma.  To evaluate the expression of the Androgen Receptor in tumor cells and stromal cells of prostatic adenocarcinoma. ix • Secondary  To correlate Tumor cell AR positivity with Gleason grade group & clinical parameters.  To correlate Stromal AR positivity with Gleason grade group & clinical parameters.